Arrowhead Pharmaceuticals ( (ARWR) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arrowhead Pharmaceuticals shares are surging after the company unveiled strong two-year results for its drug plozasiran at a major cardiology conference, showing a durable 83 percent reduction in triglycerides in patients with severe hypertriglyceridemia. The rally is being driven by investor optimism around the drug’s sustained performance and its recent regulatory approvals in several global markets.
Following the data release, several Wall Street analysts raised their price targets on Arrowhead Pharmaceuticals and reiterated buy ratings. The updated calls reflect growing confidence in the company’s RNAi pipeline as it moves closer to commercialization, reinforcing the bullish sentiment behind the stock’s sharp move higher.
More about Arrowhead Pharmaceuticals
YTD Price Performance: -3.92%
Average Trading Volume: 2,638,395
Technical Sentiment Signal: Buy
Current Market Cap: $9.12B
For further insights into ARWR stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.